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heart by integrating kilovoltage-cone beam
computed tomography in stereotactic body
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patients
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Background: To investigate the feasibility of contouring the planning risk organ volume (PRV) for the heart, and to
determine the probability of evaluating radiation dose to the heart using kilovoltage-cone beam computed
tomography (kV-CBCT) in early-stage non-small-cell lung cancer (NSCLC) patients, who received stereotactic body
radiotherapy (SBRT).
Materials and methods: Seventeen NSCLC patients who received SBRT (5Gy/f × 10f dose) were enrolled and
subjected to CBCT and CT imaging analyses to plan treatment. Sequential planning CBCT images of individual
patient’s hearts were analyzed for reproducibility of heart contouring and volume. Comparative analyses were made
between the planning CT- and CBCT-detected heart margins and dose-volume indices for treatment.
Results: The heart volume from planning CT images was significantly smaller than that from CBCT scans (p < 0.05),
and the volumes based on the different series of CBCT images were similar (p > 0.05).The overlap of the heart
region on the same anatomical section between the first series of CBCT scans and other scans reached 0.985 ±
0.020 without statistically significant differences (p > 0.05). The mean margins of the heart from planning CT and
CBCT scans were 10.5 ± 2.8 mm in the left direction, 5.9 ± 2.8 mm in the right direction, 2.2 ± 1.6 mm in the
direction of the head, 3.3 ± 2.2 mm in the direction of the foot, 6.7 ± 1.1 mm in the anterior direction, and 4.5 mm±
2.5 mm in the posterior direction. All relative and absolute dose-volume indices obtained from CBCT images were
significantly larger than those from planning CT scans (p < 0.05), with the exception of the volume in the 5Gy region.
Conclusion: The PRV of heart contouring based on kV-CBCT is feasible with good reproducibility. More accurate and
objective dose-volume indices may be obtained for NSCLC patients by using kV-CBCT, instead of CT, to plan SBRT.
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The traditional treatment for patients with early stage (I/II)
non-small cell lung carcinoma (NSCLC) is surgery [1].
Unfortunately, several counterindications to surgery exist,
such as severe comorbidity, chronic obstructive pulmonary
disease (COPD) and/or chronic heart disease [2-4]. Treat-
ments based upon radiation technology have proven useful
for NSCLC patients who are not surgical candidates; in
particular, stereotactic body radiation therapy (SBRT) has
emerged as a safe alternative [5,6].
Studies have suggested that the survival rate for SBRT
may be comparable to that for surgery [7]. Moreover,
SBRT was shown to provide better clinical outcomes
than the conventional fractionated radiotherapy (RT)
[8]. Unfortunately, SBRT carries a risk of cardiac toxicity,
which reduces its benefit on overall survival [9,10].
Specific cases of adjuvant RT-induced heart disease
offsetting improvements in cancer-specific survival have
been reported [11]; for example, breast cancer radiother-
apy was shown to increase the risk of developing ische-
mic heart disease, pericarditis, and valvular disease [12].
As a result, radiation oncologists seek to determine the
smallest cardiac dose that will provide a particular pa-
tient with the maximum efficacy and safety in treating
early-stage NSCLC.
SBRT usually involves use of kilovoltage-cone beam
computed tomography (kV-CBCT) [13,14] for treatment
set-up verification, and CBCT has high spatial resolution
and excellent soft tissue imaging capability; therefore, we
hypothesized that CBCT may be useful for delineating
hearts for the purpose of radiation dose assessment. In
addition, the time for CBCT acquisition is 75–90 sec-
onds, which can encompass several respiratory heart
motions and cardiac cycles [15]. The purpose of this
study was to use CBCT to research the reproducibility
of the heart’s planning risk volume (PRV) in early-stage
NSCLC patients. In addition, we determined PRV mar-
gins [16] for the heart in these patients and estimated
the related cardiac dosimetric parameters to perform a
comparative analysis with parameters measured by CT
scanning.
Materials and methods
Patient selection and simulation
Seventeen NSCLC patients who were scheduled to receive
SBRT (dose of 5Gy/f × 10f) were enrolled in the study be-
tween November 2010 and December 2012. All tumors
were histologically staged using the International Associ-
ation for the Study of Lung Cancer (IASLC) staging sys-
tem and were determined to be stage I or II. Patient ages
ranged between 47 and 76 years, with a median age of
61 years. The patient population included 9 males and
8 females. The pretreatment computed tomography (CT)
scanning was carried out with the patient immobilized byevacuated vacuum-bag. CT images (3 mm slice thickness)
were transferred to an Eclipse Radiotherapy Treatment
Planning System (TPS, version 8.6; Varian Medical
Systems, Palo Alto, CA, USA) for contouring and plan-
ning, according to ICRU recommendations.
The hospital’s local Institutional Review Board ap-
proved the study, and each patient provided informed
consent.
CBCT image acquisition
CBCT images were acquired before each RT session in
the treatment room using a scanner attached to the gan-
try of the Trilogy Linear Accelerator (Varian Medical
Systems). Since each RT session consisted of 10 frac-
tions, ten series of CBCT images were acquired to verify
set-up accuracy. The CBCT acquisition time was 75 –
90 s at 120 kVp, with various exposures ranging from
0.16 to 0.64 mAs per frame.
Treatment set-up
The discrepancy between planned and actual tumor pos-
ition was automatically evaluated using the software ac-
companying the Trilogy Linear Accelerator. When the
quality of a known parameter (such as boney landmarks
in the chest) was ambiguous, manual input was per-
formed to facilitate fine adjustment of the standards.
Contouring the heart on CBCT and CT images
Delineation of the heart was performed using the same
display level and window as on the planning CT. Ten
seasoned radiation oncologists were involved in contour-
ing the heart ten times for every patient on the CBCT
image and one seasoned radiotherapist was asked to
contour the heart one time on the CT image, according
to a uniform standard. The contouring criteria were as
follows: 1) based on anatomical landmarks, the boundary
between the cardiac posterior and the esophagus was
profiled according to the thickness of the esophagus that
filled with gas; 2) the boundaries between the cardiac
anterior edge, and the sternum and walls of the chest
were distinguished by their continuities of original con-
tours, as well as the CT value; 3) the boundary between
the cardiac superior edge and aorta started from the
bifurcation layer of the pulmonary artery.
To determine the boundary between the lower edge of
the heart and liver, the dropping method of CT value
was used. Briefly, we first measured the CT values of
several spots at the junction between the liver and heart
(spots were chosen based on the investigator’s experi-
ence with locating the edge of upper heart and the edge
of the junctions between the lower liver and heart). The
largest CT value of the several spots in each region was
selected and used to connect all the spots to generate a
profile of the border of the heart and liver.
Liu et al. Radiation Oncology 2013, 8:295 Page 3 of 7
http://www.ro-journal.com/content/8/1/295Calculating heart volume, heart overlap, mean heart
margins, and dose-volume indices from planning CT and
CBCT
The heart volumes from both CBCT and CT images
were determined using the Eclipse TPS. Overlapping
regions of a heart on the same anatomical section
from the series of CBCT imaging were analyzed using
MATLAB 2012a software. The mean heart margins from
planning CT and CBCT images were obtained after rec-
tification of set-up errors. Dose-volume indices were
matched by two-way scanning of the dose volume histo-
gram (DVH). Relative dose-volume indices (VxGy-R)
were: V5Gy-R
, V10Gy-R, V15Gy-R, V20Gy-R, V25Gy-R, V30Gy-R,
and V35Gy-R. Absolute dose-volume indices (VxGy-A)
were: V5Gy-A, V10Gy-A, V15Gy-A, V20Gy-A, V25Gy-A, V30Gy-A,
and V35Gy-A. Dose indices for fixed heart volume were:
D50cm
3 , D100cm
3 , D150cm
3 , D200cm
3 , D250cm
3 , and Dmean (mean
dose), Dmax (exposure dose per 1 cm
3).Statistical analysis
Data are shown as the mean ± standard error of the mean
(SEM). Analyses were performed using the Statistical
Package for Social Sciences, version 16.0 (SPSS, Chicago,
IL, USA). P-values less than 0.05 were considered statisti-
cally significant.Results
Heart volume
Figure 1 summarizes the reproducibility of heart volume
obtained from different CBCT scans, as well as a com-
parison of heart volumes between CBCT and CT images.
Heart volumes for each patient were largely similar
among CBCT images (F = 1.00, p = 0.44), but were sig-
nificantly larger than those from planning CT scans
(717 ± 100 cm3 vs. 588 ± 90 cm3; t = 4.63, p = 0.001).Figure 1 Mean heart volume of CT and CBCT images. The volume data
images from 17 patients. All other data were obtained similarly.Heart reproducibility from a series of different CBCT
images
The reproducibility of heart outlines from different
series of CBCT images of the same anatomical section
(about 40 sections from the collective RT sessions re-
ceived per patient) reached up to 0.985 ± 0.020 (Figure 2),
and the margins of error were not significantly different
between each set of images (p > 0.05) (Figure 3).
External margins in different axial directions
The margins were measured in every layer after the
registration. The maximum distance was given in six dif-
ferent axial directions in an attempt to obtain the most
protective outcomes for the heart. The mean margins in
different axial directions from the heart on planning CT
and CBCT images (pooled data values) were 10.5 ±
2.8 mm in the left direction, 5.9 ± 2.8 mm in the right
direction, 2.2 ± 1.6 mm in the direction of the head,
3.3 ± 2.2 mm in the direction of the foot, 6.7 ± 1.1 mm
in the anterior direction, and 4.5 mm ± 2.5 mm in the
posterior direction (Figure 4).
Dose-volume indices
Relative and absolute dose-volume indices from CBCT
images were significantly larger than those from CT im-
ages, with the exception of V5Gy-R (p = 0.17). In addition,
the doses in the fixed heart volumes for CBCT were sig-
nificantly larger than those for CT (p < 0.05), as shown
in Table 1 and Figure 5.
Discussion
Over the last half century, RT has evolved to become
one of the cornerstones of treatment for various types of
thoracic cancers. However, radiation-related heart dis-
ease (RRHD) resulting from radiation therapy for the
treatment of certain malignancies is becoming an in-
creasing concern for patients and clinicians alike [10,17].of CBCT1 was obtained by averaging heart volumes of the first CBCT
Figure 2 Heart reproducibility in 40 series. The fifth layer shows the worst reproducibility, which reaches more than 0.98. The coinciding heart
regions on the same anatomical section between the first series of CBCT images and other images reached up to 0.985 ± 0.020 from the first to
the 40th section.
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from acute to chronic, and can affect almost all facets of
the heart [18]. Radiation damage to the heart can occur
several months to years after treatment, and frequently
culminates in congestive heart failure, ischemia, coron-
ary artery disease, or myocardial infarction [19].
The long-term effects of RT on the cardiovascular sys-
tems remain an important research issue and studies
have shown that relative risks increase with higher radio-
therapy doses, younger age at irradiation, and the pres-
ence of conventional risk factors [17,20]. Even at lower
radiation doses, excess risk of cardiovascular disease
occurs a long time after exposure, as demonstrated in
Japanese atomic bomb survivors [21]. This makes the
biologically effective dose more complex and important,
both to the targets and to the heart, due to the increase
in dose per fraction when early-stage lung cancer cases
are treated with SBRT [8]. Hence it is of great import-
ance to accurately assess the radiation dose delivered to
the heart.
Currently, the risk of cardiac events correlates with
dose-volume predictors, which are calculated based on
planning CT images; however, these images do not re-
flect the real shape and volume of the heart, as they only
show the location and shape of the heart in each layer of
the CT image at a specific moment in time under the in-
fluence of breathing and heartbeat. Therefore, greaty
Figure 3 Reproducibility of CBCT images. CBCT images of the heart from
The reproducibility of the heart between the first CBCT (red line) and otherdifferences regarding the estimations of dose-volume
predictors for RRHD have been obtained among the
various institutional studies performed to date.
Four-dimensional computed tomography (4D-CT),
combined with a respiratory tracking system and volume
scanning to obtain dynamic time-relevant images, can
provide an accurate measure of the breathing-induced
anatomical motion of the patient [22], and can also per-
fectly eliminate the influence of respiratory movements
in clinical applications [23]. Thus, 4D-CT is now ac-
cepted as a standard tool for simulation and treatment
planning in lung SBRT [24,25]. Compared to the length
of respiratory movements, however, the heartbeat is so
short that 4D-CT cannot accurately reflect the heart’s
condition. The best way to evaluate irradiation dose of
the heart is application of the electrocardiography gating
dynamic magnetic resonance imaging (MRI) analysis.
However, deformable image registration is needed for
different MRI phase images and the registration between
MRI and planning CT. The accumulation among differ-
ent phase dose are also required. Furthermore, these
technologies have not yet formed a mature evaluation
process.
It is important to note that the electrocardiographically-
gated method cannot be used to simulate CT in determin-
ing the heart PRV. Since SRBT patients generally require a
high irradiation field dose and long irradiation time, it isX
one representative patient show overlap of the anatomical region.
images (blue line) are shown on the sectional and coronal planes.
Figure 4 External margins in different axial directions. The margin on the sectional direction is 0.91 cm and 1.29 cm on the coronal plane.
Similar margins were obtained for all other patient presented.
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of the SBRT is anticipated to solve this problem. Truebeam
is able to reach a dose rate of 2400 MU/min, but its repro-
ducibility is weak. At present, only a few reports about the
efficacy and safety of SBRT in combination with ABC exist.Table 1 Dose-volume indices between CBCT and CT
Parameter CBCT, ± SEM CT, ± SEM t P
V5Gy-R
a 47.7 ± 16.4% 49.0 ± 16.0% 1.5 0.17
V10Gy-R 18.9 ± 11.7% 17.4 ± 11.8% 2.3 0.03
V15Gy-R 14.4 ± 10.2% 12.8 ± 10.4% 2.3 0.02
V20Gy-R 10.5 ± 9.0% 9.0 ± 8.9% 2.3 0.04
V25Gy-R 6.6 ± 2.8% 4.5 ± 2.3% 3.6 0.01
V30Gy-R 4.2 ± 2.2% 2.5 ± 1.6% 3.7 0.01
V35Gy-R 3.2 ± 1.8% 1.7 ± 1.3% 3.9 0.01
V5Gy-A
b 333.0 ± 78.4 cm
3 282.0 ± 61.7 cm
3 7.9 0.0001
V10Gy-A 133.0 ± 68.6 cm
3 101.0 ± 59.0 cm
3 6.8 0.0001
V15Gy-A 102.0 ± 62.6 cm
3 74.6 ± 53.7 cm
3 6.2 0.0001
V20Gy-A 74.0 ± 55.8 cm
3 52.5 ± 46.4 cm
3 4.8 0.0001
V25Gy-A 46.0 ± 16.9 cm
3 27.0 ± 12.0 cm
3 6.2 0.0001
V30Gy-A 30.0 ± 14.4 cm
3 15.0 ± 8.7 cm
3 5.5 0.0001
V35Gy-A 24.0 ± 12.0 cm
3 10.0 ± 7.0 cm
3 5.5 0.0001
D50cm
3 c 19.9 ± 7.7 Gy 17.1 ± 6.3 Gy 4.5 0.0001
D100cm
3 15.3 ± 6.2 Gy 12.8 ± 5.7 Gy 3.6 0.003
D150cm
3 11.8 ± 5.5 Gy 9.2 ± 3.4 Gy 3.6 0.003
D200cm
3 8.2 ± 2.0 Gy 6.8 ± 1.5 Gy 6.2 0.0001
D250cm
3 6.4 ± 1.7 Gy 5.2 ± 2.0 Gy 6.5 0.0001
Dmean 7.0 ± 2.8 Gy 6.5 ± 2.4 Gy 3.0 0.009
Dmax 45.7 ± 13.1 Gy 45.1 ± 13.5 Gy 2.9 0.009
a). V5Gy-R means the heart relative volume in the 5Gy region, V10Gy-R, V15Gy-R,
V20Gy-R, V25Gy-R, V30Gy-R, and V35Gy-R are of the same mean;
b). V5Gy-A means the heart absolute volume in the 5Gy region, V10Gy-A, V15Gy-A,
V20Gy-A, V25Gy-A, V30Gy-A, and V35Gy-A are of the same mean;
c). D50cm
3 means the exposure dose in the 50 cm3, D100cm
3 , D150cm
3 , D200cm
3 , and
D250cm
3 are of the same mean.CBCT imaging, which encompasses several respiratory
and cardiac movement cycles, represents an effective means
of graphing the heart PRV to plan for SBRT. Using a rotat-
ing kilovoltage x-ray source and a flat panel detector has
improved the CBCT technique [15,26]. In addition, not
only can CBCT enhance the precision of radiotherapy for
target volumes, but it can also reduce the radiation volume
and dose for organs at risk [27]. As reported by Nakamura
et al., free-breathing CBCTacts as a slow CT scan that con-
tains target motion [28]. The kV-CBCT scan period is rela-
tively long (75 – 90 s), and includes 12–20 respiratory
cycles and more than 100 cardiac cycles [13]. This feature
allows the avoidance of the influence of respiratory and car-
diac movements, resulting in a more accurate representa-
tion of the heart’s motion. The CBCT scan also includes the
movements of many organs, so it has unique advantages for
researching the PRV of the heart. Topolnjak et al. applied
CBCT to studying the PRV of the heart in the treatment of
breast cancer, and presented specific external margins [29];
however, their research only considered the breathing cycles
and failed to include the influence of heartbeats.
In the current study, the heart was contoured under a
unified standard with the application of CBCT and in-
cluded breathing and heartbeat, which are the two main
factors that influenced the heart location in the thoracic
cavity. In addition, the external margins were calculated
by comparison with planning CT images, which could
better reflect the actual location of the heart. Finally, all
relative and absolute dose-volume indices were com-
pared in this study because there is not a clear relation-
ship between dose-volume indices and RRHD [9]. The
poor image quality and motion artifact of the CBCT
could have an impact on contouring the heart. This
impact could be minimized by the following methods:
1. The kV-CBCT scan period was so long that the
image change caused by motion might be blurred.
Figure 5 Mean heart DVH of CT and CBCT images. Relative dose-volume indices were calculated through the DVH and caves (red line for CT
and blue line for CBCT) were obtained using MATLAB 2012a. The two caves are separated.
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be reduced, while the setup error was corrected
using the chest bony landmarks as the judgment
standard.
2. After the registration of CBCT image to the
planning CT images, delineation of the heart would
be performed in the same window as the CT.
3. When the heart was closed to the surrounding
tissues, the dropping method of CT value was used
to distinguish the heart from the surrounding
tissues.
4. In this paper, the outline of the heart was contoured
and fine structure, such as the left anterior descending
coronary artery, was not delineated. Therefore, the
CBCT image resolution was sufficient to contour the
heart.
There was 95% reproducibility of heart images based on
10 CBCT scans, which manifested as overlapping of the
heart’s region on the same anatomical section between the
first series of CBCT scans; the error of the heart volume
was within 5%. For this reason, the heart graph and vol-
ume from the first CBCT scan were enough to replace the
others. In this way, the time of heart contouring based on
CBCT can be reduced, which can also relieve the risk to
the heart from the CBCT, particularly for patients who
have a history of heart disease.
By comparing the first series of heart CBCT and CT
images, we found that the heart boundary from CBCT
images was larger than that from CT images, and the
difference was even greater in the left anterior lower
area of heart where the heart movement was most obvi-
ous with the largest distance of 13 mm. Throughout the
study, we concluded that it was necessary to conduct
CBCT scans in patients who might suffer RRHD when
receiving SBRT for treatment of NSCLC.
Although heart ranges based on CBCT images were
larger than those based on CT scans, their boundaries
were much closer to the tumor. Therefore, the relativeand absolute dose-volume indices correspondingly be-
came larger. With the additional comparison of dosi-
metric parameters in DVHs, all indices for heart doses
based on CBCT scans were larger than those based on
CT scans, with the exception of V5Gy-R. Therefore, the
application of kV-CBCT for the estimation of radiation
doses to the heart is a better method for protecting the
heart in early stage NSCLC patients receiving SBRT
treatment. Furthermore, for patients with tumors near
the heart or who are inoperable due to heart disease, it
is extremely important to accurately estimate the radi-
ation dosage to the heart and to forecast cardiac injury
with the application of CBCT. This technique provides a
more objective, scientific and general method of heart
dose estimation in the application of SBRT for treating
early-stage NSCLC. Our future studies will include ana-
lyses of the relevance between CBCT dose-volume indi-
ces and RRHD.
In conclusion, determining the PRV of heart contour-
ing based on kV-CBCT is feasible and shows good re-
producibility. More accurate and objective dose-volume
indices may be obtained from applying kV-CBCT in the
SBRT of early-stage NSCLC patients.
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